Clinical value of miR-23a-3p expression in early diagnosis of diabetic kidney disease
Open accessAbstract
INTRODUCTION: The objective was to observe the expression of miR-23a-3p in the serum of patients with type 2 diabetic nephropathy (T2DN) and to explore its clinical significance. MATERIALS AND METHODS: 112 patients with type 2 diabetes were divided into a simple diabetes mellitus (NON) group, T2DN microalbuminuria (MIC) group, and T2DN macroalbuminuria (MAC) group, according to the urinary protein-creatinine ratio (uACR). Clinical data were collected, miR-23a-3p levels in serum were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR), and clinical parameters were measured by an automatic biochemical analyser; the influencing factors of diabetic kidney disease (DKD) and the correlation between miR-23a-3p expression and clinical parameters were analysed. RESULTS: The expression of miR-23a-3p in the serum of the DKD group was lower than that of the normal control (CON) and NON groups. Correlation analysis showed that miR-23a-3p was positively correlated with urinary albumin (Albu), glycosylated haemoglobin (HbA1c), total cholesterol (CHOL), glycated albumin (GA-L), serum creatinine (Scr), fasting blood glucose (GLU), and uric acid (UA), negatively correlated with uACR and high-density lipoprotein cholesterol (HDL-C), but not correlated with urinary creatinine (CREA). The area under the receiver operating characteristic (ROC) curve (AUC) of miR-23a-3p for the diagnosis of DKD was 0.686 [95% confidence interval (CI): 0.599-0.773], with a sensitivity of 64.5% and a specificity of 71.2%; the AUC for differentiating NON from DKD was 0.700 (95% CI: 0.598-0.802), with a sensitivity of 61.8% and a specificity of 77.8%. Multivariate logistic regression analysis showed that serum miR-23a-3p levels were not associated with the development of DKD after adjusting for other levels of influence and were not significant for the differentiation of NON and DKD. CONCLUSION: Serum miR-23a-3p levels are decreased in T2DN patients, and this change becomes more significant with the severity of the disease, which may be a marker for the early diagnosis and progression of T2DN.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In type 2 diabetic nephropathy patients (112 cases), miR-23-3p expression is decreased in serum, lower than both the control group and the simple diabetes group, and the decrease is more significant with increasing disease severity.
“the expression level of miR-23–3p was observed to be decreased in the serum of Type 2 diabetic nephropathy (T2DN) patients (totally 112 cases), with levels being lower than both the control group and the simple diabetes group. Furthermore, this decrease was more significant with increasing severity of the disease [12,16].”
From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [16]
The ‘Comparison of serum miR-23a-3p levels’ section (page not specified) reports progressively lower serum levels across the control, simple-diabetes, microalbuminuria and macroalbuminuria groups. However, Table 2 (page not specified) shows 112 patients with diabetes in total, of whom 76—not 112—were in the nephropathy groups. The source also identifies the molecule as miR-23a-3p, rather than miR-23-3p. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 16 · Cited by 9
- Authors
- Meng, X., Yu, X., & Lei, P.
- Affiliations
- Qingdao University (CN)
- Venue
- Endokrynologia Polska
- Publisher
- VM Media Group sp. z o.o
- Published
- 2023-07-27
- ISSN
- 0423-104X (ISSN-L)
- 2299-8306
- OpenAlex
- W4385798417
- Cited by
- 9
- References
- 16
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 1
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Endokrynologia Polska (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- miR-23a-3p, diabetic nephropathy, type 2 diabetic nephropathy, early diagnosis, serum microRNA, microalbuminuria, macroalbuminuria, urinary albumin, HbA1c, glycemic control, biomarkers, sensitivity and specificity, dyslipidemia, uric acid, serum creatinine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
